Curcuphenol compounds for increasing MHC-I expression

1. A method for increasing major histocompatibility complex class I (MHC-1) surface expression in a cancer cell, comprising contacting the cancer cell with a curcuphenol compound, wherein said cancer is a carcinoma and wherein said curcuphenol compound has the structure:

2. The method of claim 1 , where the cell in its untreated state is characterized by reduced MHC-1 surface expression and relative to a normal or otherwise healthy cell of the same cell type wherein MHC-1 surface expression in the cell is increased to within about 10% of the levels of MHC-1 surface expression of the otherwise normal or healthy cell of the same cell type.

3. The method of claim 1 , wherein the cancer cell is selected from one or more of a prostate cancer cell, and a lung cancer cell.

4. The method of claim 1 , wherein the cell is in a subject, and the method comprises administering the curcuphenol compound to the subject; wherein the subject has cancer, wherein said cancer is a carcinoma.

5. The method of claim 4 , wherein the cancer is characterized by cancer cells in an untreated state having reduced MHC-1 surface expression and reduced TAP-1 expression relative to non-cancerous cells of the same cell type.

6. The method of claim 5 , wherein MHC-1 surface expression and TAP-1 expression in the cancer cell(s) is increased by at least about 10% relative to a control cell wherein increased MHC-1 surface expression and TAP-1 expression increases a CTL-mediated immune response against the cancer cells.

7. The method of claim 4 , wherein the cancer is selected from one or more of prostate cancer, and lung cancer.

8. The method of claim 4 , comprising administering the curcuphenol compound in combination with an additional cancer therapy wherein optionally the additional cancer therapy selected from one or more of an anti-cancer agent, radiotherapy, surgery, transplantation, photodynamic therapy, symptomatic care, and antibiotic therapy wherein optionally the anti-cancer agent is selected from a small molecule and an antibody wherein optionally the small molecule is a cytotoxic, chemotherapeutic, or anti-angiogenic agent wherein optionally the small molecule cytotoxic, chemotherapeutic, or anti-angiogenic agent is selected from one or more of alkylating agents, anti-metabolites, anthracyclines, anti-tumor antibiotics, platinums, type I topoisomerase inhibitors, type II topoisomerase inhibitors, vinca alkaloids, and taxanes wherein optionally the small molecule is selected from one or more of chlorambucil, cyclophosphamide, cilengitide, lomustine (CCNU), melphalan, procarbazine, thiotepa, carmustine (BCNU), enzastaurin, busulfan, daunorubicin, doxorubicin, gefitinib, erlotinib idarubicin, temozolomide, epirubicin, mitoxantrone, bleomycin, cisplatin, carboplatin, oxaliplatin, camptothecins, irinotecan, topotecan, amsacrine, etoposide, etoposide phosphate, teniposide, temsirolimus, everolimus, vincristine, vinblastine, vinorelbine, vindesine, CT52923, paclitaxel, imatinib, dasatinib, sorafenib, pazopanib, sunitnib, vatalanib, geftinib, erlotinib, AEE-788, dichoroacetate, tamoxifen, fasudil, SB-681323, semaxanib, donepizil, galantamine, memantine, rivastigmine, tacrine, rasigiline, naltrexone, lubiprostone, safinamide, istradefylline, pimavanserin, pitolisant, isradipine, pridopidine (ACR16), tetrabenazine, bexarotene, glatirimer acetate, fingolimod, and mitoxantrone, including pharmaceutically acceptable salts and acids thereof where optionally the antibody is selected from one or more of 3F8, 8H9, abagovomab, adecatumumab, afutuzumab, alacizumab (pegol), alemtuzumab, altumomab pentetate, amatuximab, anatumomab mafenotox, apolizumab, arcitumomab, bavituximab, bectumomab, belimumab, bevacizumab, bivatuzumab (mertansine), brentuximab vedotin, cantuzumab (mertansine), cantuzumab (ravtansine), capromab (pendetide), carlumab, catumaxomab, cetuximab, citatuzumab (bogatox), cixutumumab, clivatuzumab (tetraxetan), conatumumab, dacetuzumab, daclizumab, dalotuzumab, detumomab, drozitumab, ecromeximab, edrecolomab, elotuzumab, enavatuzumab, ensituximab, epratuzumab, ertumaxomab, etaracizumab, farletuzumab, FBTA05, figitumumab, flanvotumab, galiximab, gemtuzumab, ganitumab, gemtuzumab (ozogamicin), girentuximab, glembatumumab (vedotin), ibritumomab tiuxetan, icrucumab, igovomab, indatuximab ravtansine, intetumumab, inotuzumab ozogamicin, ipilimumab (MDX-I0I), iratumumab, labetuzumab, lexatumumab, lintuzumab, lorvotuzumab (mertansine), lucatumumab, lumiliximab, mapatumumab, matuzumab, milatuzumab, mitumomab, mogamulizumab, moxetumomab (pasudotox), nacolomab (tafenatox), naptumomab (estafenatox), narnatumab, necitumumab, nimotuzumab, nivolumab, Neuradiab® (with or without radioactive iodine), NR-LU-10, ofatumumab, olaratumab, onartuzumab, oportuzumab (monatox), oregovomab, panitumumab, patritumab, pemtumomab, pertuzumab, pritumumab, racotumomab, radretumab, ramucirumab, rilotumumab, rituximab, robatumumab, samalizumab, sibrotuzumab, siltuximab, tabalumab, tanezumab, taplitumomab (paptox), tenatumomab, teprotumumab, TGN1412, ticilimumab, trastuzumab, tremelimumab, tigatuzumab, TNX-650, tositumomab, TRBS07, tucotuzumab (celmoleukin), ublituximab, urelumab, veltuzumab, volociximab, votumumab, and zalutumumab, including antigen-binding fragments thereof.

9. The method of claim 1 , wherein the cancer cell, is a metastatic cancer cell.

10. The method of claim 1 , wherein the cancer cell is a lung cancer cell.

11. The method of claim 10 , wherein the lung cancer cell is selected from the group consisting of an adenocarcinoma, squamous-cell lung carcinoma, small-cell lung carcinoma, and a large-cell lung carcinoma.

12. The method of claim 2 , where the cell in its untreated state is characterized by reduced TAP-1 expression relative to a normal or otherwise healthy cell of the same cell type wherein TAP-1 expression in the cell is increased to within about 10% TAP-1 expression of the otherwise normal or healthy cell of the same cell type.